NCT06548204View on ClinicalTrials.gov

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Interventions
DRUG

Fexofenadine Hydrochloride 60mg bid

Fexofenadine hydrochloride 60mg bid treatment for 6 months.

OTHER

Placebo

Placebo administration for 6 months.

DRUG

Fexofenadine Hydrochloride 120mg bid

Fexofenadine hydrochloride 120mg bid treatment for 6 months.

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06548204 - Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial | Biotech Hunter | Biotech Hunter